Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study

Claire N. Harrison, Nicolaas Schaap, Alessandro M. Vannucchi, Jean Jacques Kiladjian, Ramon V. Tiu, Pierre Zachee, Eric Jourdan, Elliott Winton, Richard T. Silver, Harry C. Schouten, Francesco Passamonti, Sonja Zweegman, Moshe Talpaz, Joanne Lager, Zhenming Shun, Ruben A. Mesa

Research output: Contribution to journalArticlepeer-review

100 Scopus citations

Fingerprint Dive into the research topics of 'Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study'. Together they form a unique fingerprint.

Medicine & Life Sciences